This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.15% per year. These returns cover a period from January 1, 1988 through June 3, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Headquartered in Woonsocket, RI, CVS Health Corporation (formerly known as CVS Caremark Corporation) is a pharmacy innovation company with integrated offerings across the entire spectrum of pharmacy care. On Sep 3, 2014, CVS Caremark Corporation announced a change of its corporate name to CVS Health to reflect its broader health care commitment. In Nov 2018, CVS Health completed the $70-billion consolidation of insurance-giant Aetna. With the acquisition, the segments of CVS Health have been realigned.
CVS Health (CVS) Misses Q1 Earnings and Revenue Estimates
by Zacks Equity Research
CVS Health (CVS) delivered earnings and revenue surprises of -22.49% and 0.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?
CVS Health (CVS) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
CVS Health (CVS) closed at $67.18 in the latest trading session, marking a -0.22% move from the prior day.
Gear Up for CVS Health (CVS) Q1 Earnings: Wall Street Estimates for Key Metrics
by Zacks Equity Research
Looking beyond Wall Street's top -and-bottom-line estimate forecasts for CVS Health (CVS), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended March 2024.
Why CVS Health (CVS) Dipped More Than Broader Market Today
by Zacks Equity Research
The latest trading day saw CVS Health (CVS) settling at $67.33, representing a -0.65% change from its previous close.
Earnings Preview: CVS Health (CVS) Q1 Earnings Expected to Decline
by Zacks Equity Research
CVS Health (CVS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Think CVS Health (CVS) Is a Good Investment: Is It?
by Zacks Equity Research
The average brokerage recommendation (ABR) for CVS Health (CVS) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
CVS Health (CVS) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
In the most recent trading session, CVS Health (CVS) closed at $69.75, indicating a +0.52% shift from the previous trading day.
CVS Health (CVS) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
CVS Health (CVS) closed at $69.39 in the latest trading session, marking a +1.15% move from the prior day.
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
CVS Health (CVS) to Report Q1 Earnings: What's in the Cards?
by Zacks Equity Research
The strength of a diversified enterprise, along with robust operational execution, is expected to be reflected in CVS Health's (CVS) first-quarter 2024 results.
CVS Health (CVS) Declines More Than Market: Some Information for Investors
by Zacks Equity Research
In the closing of the recent trading day, CVS Health (CVS) stood at $68.64, denoting a -1.58% change from the preceding trading day.
CVS Health (CVS) Stock Drops Despite Market Gains: Important Facts to Note
by Zacks Equity Research
CVS Health (CVS) closed at $73.36 in the latest trading session, marking a -1.45% move from the prior day.
Here is What to Know Beyond Why CVS Health Corporation (CVS) is a Trending Stock
by Zacks Equity Research
Recently, Zacks.com users have been paying close attention to CVS Health (CVS). This makes it worthwhile to examine what the stock has in store.
Fastenal (FAST) to Post Q1 Earnings: What's in the Cards?
by Zacks Equity Research
Fastenal's (FAST) Q1 results are likely to reflect manufacturing growth, albeit at a slow pace, with a strong digital strategy and a balanced onsite/offsite mix. Yet, slowing industrial markets are a concern.
CVS Health (CVS) Is Considered a Good Investment by Brokers: Is That True?
by Zacks Equity Research
Based on the average brokerage recommendation (ABR), CVS Health (CVS) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?
Zacks Industry Outlook Highlights CVS Health, Walgreens Boots Alliance, Herbalife and Amazon
by Zacks Equity Research
CVS Health, Walgreens Boots Alliance, Herbalife and Amazon have been highlighted in this Industry Outlook article.
CVS Health (CVS) Outperforms Broader Market: What You Need to Know
by Zacks Equity Research
CVS Health (CVS) closed the most recent trading day at $74.60, moving +1.06% from the previous trading session.
2 Retail Pharmacy Stocks to Watch and One to Avoid Amid Industry Headwinds
by Urmimala Biswas
Zacks Retail-Pharmacies and Drug Stores industry players like CVS and WBA are likely to gain despite reimbursement challenges that are hurting the overall health industry. HLF might face the wrath of economic challenges.
CVS Health Corporation (CVS) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
CVS Health (CVS) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Health Insurance Stocks Drop: Insights Into the Late Monday Fall
by Kaibalya Pravo Dey
Higher costs and lower hikes in rates can lead to lower profit growth, which concerns investors.
These 2 Retail and Wholesale Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Should You Invest in the iShares U.S. Healthcare Providers ETF (IHF)?
by Zacks Equity Research
Sector ETF report for IHF
Will CVS Health (CVS) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
CVS Health (CVS) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
These 2 Retail and Wholesale Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
CVS Health (CVS) Ascends But Remains Behind Market: Some Facts to Note
by Zacks Equity Research
CVS Health (CVS) concluded the recent trading session at $79.43, signifying a +0.14% move from its prior day's close.